Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Mass deworming experiment aims to wipe out parasitic worms in three countries

NCT ID NCT03014167

Disease control Sponsor: University of Washington Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This massive study tested whether giving deworming medicine (albendazole) to everyone in a community, not just children, can break the cycle of soil-transmitted worm infections. Over 350,000 people in India, Malawi, and Benin took part. The goal was to see if treating entire villages for three years could reduce infections to very low levels and keep them there.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Albendazole (a deworming drug)
What this could lead to
If successful, this could show that treating entire communities with deworming medicine can stop the spread of soil-transmitted worms, leading to simpler and more effective public health programs.
What could go wrong
The trial is very large but results may vary by region. Even if transmission drops, worms could return if treatment stops. Also, the drug is not given to pregnant women in early pregnancy or very young children, which could limit impact.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

357,716 people

The number who actually took part.

Started

Oct 2017

Finished

Jul 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 months and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Treatment Inclusion Criteria: * Ages 12 months and older Treatment Exclusion Criteria: * Children under 12 months of age * Pregnant women in their first trimester * History of adverse reaction to benzimidazoles Outcome Sampling Inclusion Criteria: * Resident of study clusters * Ages 12 months and older * Willingness of adult aged 18 years and above (or age as per country specific ethical guidelines) or parent/guardian of child to provide written informed consent * Provision of written assent to participate from children aged 8 years and above (or age as per country specific ethical guidelines) Outcome Sampling Exclusion Criteria: * Less than 12 months of age * Individuals who do not typically reside in the study cluster * Nonconsenting or assenting individuals, as applicable

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Filariasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

filarial elephantiasis filariasis helminthiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Filariasis Helminthiasis

Contacts and locations

Locations

  • Christian Medical College

    Vellore, India

  • Institut de Recherche pour le Développement

    Comé, Benin

  • London School of Hygiene and Tropical Medicine

    Mangochi, Malawi

More trials for these conditions

Other studies related to the condition(s) this trial covers.